Application Of Dna Probes To Antimicrobial Susceptibility Testing Of Legionella-Pneumophila

The commercial availability of a DNA probe assay for the detection of Legionella (Gen-Probe Incorporated, San Diego, CA) provides a unique opportunity to investigate the application of this technology to antibiotic susceptibility testing of L. pneumophila. We examined the ability of erythromycin, rifampin, and ciprofloxacin to kill L. pneumophila in buffered ACES-yeast extract broth (YEB). The test organism was incubated for a total of 96 hr in the presence of 10-mu-g/ml erythromycin, 1-mu-g/ml rifampin, or 1-mu-g/ml ciprofloxacin. Growth was monitored at 24-hr intervals by quantitative plating and the DNA probe assay. The correlation between organism concentration [colony-forming units (CFU) per ml] and DNA probe activity (counts per min) was excellent (r = 0.97). The percent decrease in CFU/ml at 96 hr relative to control counts was > 99% for erythromycin, rifampin, and ciprofloxacin. The percent decrease in CPM at 96 hr versus control was 87% for erythromycin, 89% for rifampin, and 93% for ciprofloxacin. This data documents a novel application of DNA probe technology, which may be useful in future studies of in vitro susceptibility of Legionella to various agents.